Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
South Korea · Delayed Price · Currency is KRW 3,200.00
-30.00 (-0.93%)
At close: Apr 9, 2026
Kangstem Biotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,572 | 7,746 | 12,704 | 16,301 | 12,405 |
Other Revenue | - | - | -0 | -0 | -0 |
| 3,572 | 7,746 | 12,704 | 16,301 | 12,405 | |
Revenue Growth (YoY) | -53.88% | -39.03% | -22.06% | 31.41% | 35.75% |
Cost of Revenue | 2,727 | 3,420 | 11,061 | 11,428 | 9,716 |
Gross Profit | 845.01 | 4,325 | 1,643 | 4,873 | 2,689 |
Selling, General & Admin | 5,822 | 6,990 | 10,272 | 11,076 | 10,636 |
Research & Development | 12,577 | 12,143 | 14,030 | 14,220 | 14,653 |
Amortization of Goodwill & Intangibles | 22.65 | 0.26 | 75.32 | 91.02 | 95.55 |
Operating Expenses | 18,513 | 19,168 | 24,420 | 25,431 | 25,424 |
Operating Income | -17,668 | -14,842 | -22,777 | -20,558 | -22,736 |
Interest Expense | -492.67 | -425.94 | -893.42 | -761.13 | -761.09 |
Interest & Investment Income | 784.57 | 1,456 | 1,534 | 1,218 | 742.09 |
Currency Exchange Gain (Loss) | -6.88 | -3.4 | -2.94 | 56.62 | 50.27 |
Other Non Operating Income (Expenses) | 20.66 | 141.59 | 29.1 | 143.53 | -30.07 |
EBT Excluding Unusual Items | -17,362 | -13,674 | -22,110 | -19,901 | -22,734 |
Gain (Loss) on Sale of Investments | 6,855 | 6,629 | -872.13 | -308.46 | -348.21 |
Gain (Loss) on Sale of Assets | 39.63 | -37.1 | 95.52 | -5.6 | 1,272 |
Asset Writedown | - | - | -250.52 | - | - |
Pretax Income | -10,467 | -7,083 | -23,137 | -20,215 | -21,811 |
Income Tax Expense | - | - | 83.71 | -38.96 | 15.8 |
Earnings From Continuing Operations | -10,467 | -7,083 | -23,221 | -20,176 | -21,827 |
Earnings From Discontinued Operations | - | -907.1 | - | - | - |
Net Income to Company | -10,467 | -7,990 | -23,221 | -20,176 | -21,827 |
Minority Interest in Earnings | -14.71 | 320.53 | 1,272 | -59.78 | 478.45 |
Net Income | -10,482 | -7,669 | -21,949 | -20,236 | -21,348 |
Net Income to Common | -10,482 | -7,669 | -21,949 | -20,236 | -21,348 |
Shares Outstanding (Basic) | 69 | 56 | 41 | 38 | 28 |
Shares Outstanding (Diluted) | 69 | 56 | 41 | 38 | 28 |
Shares Change (YoY) | 23.10% | 38.90% | 7.02% | 36.23% | 24.89% |
EPS (Basic) | -151.00 | -136.00 | -540.61 | -533.40 | -766.61 |
EPS (Diluted) | -151.00 | -136.00 | -540.61 | -533.40 | -766.61 |
Free Cash Flow | -12,337 | -19,581 | -17,890 | -19,576 | -21,624 |
Free Cash Flow Per Share | -177.72 | -347.22 | -440.63 | -516.01 | -776.52 |
Gross Margin | 23.65% | 55.84% | 12.93% | 29.89% | 21.68% |
Operating Margin | -494.56% | -191.62% | -179.29% | -126.12% | -183.28% |
Profit Margin | -293.41% | -99.01% | -172.77% | -124.14% | -172.10% |
Free Cash Flow Margin | -345.33% | -252.79% | -140.82% | -120.10% | -174.32% |
EBITDA | -15,304 | -11,616 | -18,862 | -16,688 | -18,862 |
EBITDA Margin | - | -149.97% | -148.47% | -102.37% | -152.05% |
D&A For EBITDA | 2,364 | 3,226 | 3,915 | 3,871 | 3,874 |
EBIT | -17,668 | -14,842 | -22,777 | -20,558 | -22,736 |
EBIT Margin | - | -191.62% | -179.29% | -126.12% | -183.28% |
Advertising Expenses | 134.21 | 154.71 | 199.08 | 533.74 | 589.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.